Non-High-Density Lipoprotein Cholesterol as a Biomarker for Nonalcoholic Steatohepatitis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 6, 2012, Pages 651-656

  Corey, Kathleen E ^a,b   Lai, Michelle ^b,c   Gelrud, Louis G ^d   Misdraji, Joseph ^a,b   Barlow, Lydia L ^a   Zheng, Hui ^a,b   Andersson, Karin L ^a,b   Thiim, Michael ^a,b   Pratt, Daniel S ^a,b   Chung, Raymond T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Bon Secours Richmond Health System   (United States)

Author keywords

Blood Test; Clinical Trial; Diagnostic; Nonalcoholic Fatty Liver Disease

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STEATOSIS;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CLINICAL LABORATORY TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84861332191     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.01.017     Document Type: Article

References (28)

1. Dunn W., Xu R., Wingard D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008, 103:2263-2271.
2. Gholam P.M., Flancbaum L., Machan J.T., et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102:399-408.
3. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600-606.
4. Ekstedt M., Franzén L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
5. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
6. Fujita K., Nozaki Y., Wada K., et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009, 50:772-780.
7. Adiels M., Olofsson S.O., Taskinen M.R., et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
8. Choi S.S., Diehl A.M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008, 19:295-300.
9. Sundaram M., Yao Z. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) 2010, 7:35.
10. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
11. Choi C.S., Savage D.B., Kulkarni A., et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007, 282:22678-22688.
12. Arsenault B.J., Rana J.S., Stroes E.S., et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009, 55:35-41.
13. Orakzai S.H., Nasir K., Blaha M., et al. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis 2009, 202:289-295.
14. Robinson J.G., Wang S., Smith B.J., et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009, 53:316-322.
15. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004, 44:720-732.
16. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008, 51:1512-1524.
17. Charlton-Menys V., Betteridge D.J., Colhoun H., et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009, 55:473-480.
18. Feldstein A.E., Wieckowska A., Lopez A.R., et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
19. Wieckowska A., Papouchado B.G., Li Z., et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008, 103:1372-1379.
20. Wieckowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
21. Hossain N., Afendy A., Stepanova M., et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1224-1229.
22. Alkhouri N., Tamimi T.A., Yerian L., et al. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci 2009, 55:2644-2650.
23. Lemoine M., Ratziu V., Kim M., et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009, 29:1431-1438.
24. Shah A.G., Lydecker A., Murray K., et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1104-1112.
25. Robinson J.G. Are you targeting non-high-density lipoprotein cholesterol?. J Am Coll Cardiol 2009, 55:42-44.
26. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51:1947-1953.
27. Foster T., Budoff M.J., Saab S., et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106:71-77.
28. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54:344-353.